Sanofi's multiple myeloma drug just got a major upgrade. The FDA has approved Sarclisa Escena, a wearable on-body injector version of Sarclisa (isatuximab), giving patients a subcutaneous alternative to lengthy intravenous infusions. The new delivery method could cut down time spent in infusion centers and ease the workload on oncology clinics.
Sanofi's multiple myeloma drug just got a major upgrade.
The FDA has approved Sarclisa Escena, a wearable on-body injector form of Sanofi's blood cancer drug Sarclisa (isatuximab). Designed for patients with multiple myeloma — a rare blood cancer originating in the bone marrow's plasma cells — the device delivers the drug subcutaneously through a wearable injector attached to the skin, offering a far less burdensome alternative to traditional IV infusions.
The original intravenous formulation of Sarclisa first received FDA approval back in 2020 for relapsed multiple myeloma. This new subcutaneous version marks a meaningful step forward in patient convenience and clinic efficiency, particularly for those undergoing repeated treatment courses.
Key Takeaways:
Why it matters: For multiple myeloma patients who require ongoing treatment, switching from IV infusions to a wearable injector could meaningfully improve quality of life — fewer hours in the clinic, less disruption to daily routines, and a more manageable treatment experience overall.
